Ian H Gilbert

List of Publications by Year
in descending order

188	9,496	36303 51	51608 86
papers	citations	h-index	g-index

198	198	198	10721
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention. Cell Chemical Biology, 2022, 29, 191-201.e8.	5.2	39
2	Identification of a Proteasome-Targeting Arylsulfonamide with Potential for the Treatment of Chagasâ€™ Disease. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0153521.	3.2	11
3	Compounds enhancing human sperm motility identified using a high-throughput phenotypic screening platform. Human Reproduction, 2022, 37, 466-475.	0.9	6
4	High-throughput phenotypic screening of the human spermatozoon. Reproduction, 2022, 163, R1-R9.	2.6	3
5	Repositioning of a Diaminothiazole Series Confirmed to Target the Cyclin-Dependent Kinase CRK12 for Use in the Treatment of African Animal Trypanosomiasis. Journal of Medicinal Chemistry, 2022, 65, 5606-5624.	6.4	8
6	High-Throughput Screening Platform To Identify Inhibitors of Protein Synthesis with Potential for the Treatment of Malaria. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	10
7	Plasmodium Kinases as Potential Drug Targets for Malaria: Challenges and Opportunities. ACS Infectious Diseases, 2021, 7, 518-534.	3.8	39
8	Mycobacterium tuberculosis Phe-tRNA synthetase: structural insights into tRNA recognition and aminoacylation. Nucleic Acids Research, 2021, 49, 5351-5368.	14.5	1
9	Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2021, 64, 5905-5930.	6.4	25
10	Multiple unbiased approaches identify oxidosqualene cyclase as the molecular target of a promising anti-leishmanial. Cell Chemical Biology, 2021, 28, 711-721.e8.	5.2	11
11	MalDA, Accelerating Malaria Drug Discovery. Trends in Parasitology, 2021, 37, 493-507.	3.3	51
12	Ligand binding: evaluating the contribution of the water molecules network using the Fragment Molecular Orbital method. Journal of Computer-Aided Molecular Design, 2021, 35, 1025-1036.	2.9	8
13	Towards the sustainable discovery and development of new antibiotics. Nature Reviews Chemistry, 2021, 5, 726-749.	30.2	439
14	Synthesis of a Series of Diaminoindoles. Journal of Organic Chemistry, 2021, 86, 11333-11340.	3.2	2
15	Prioritization of Molecular Targets for Antimalarial Drug Discovery. ACS Infectious Diseases, 2021, 7, 2764-2776.	3.8	35
16	DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2021, 64, 16159-16176.	6.4	31
17	A platform for target prediction of phenotypic screening hit molecules. Journal of Molecular Graphics and Modelling, 2020, 95, 107485.	2.4	1
18	Setting Our Sights on Infectious Diseases. ACS Infectious Diseases, 2020, 6, 3-13.	3.8	17

#	Article	IF	Citations
19	Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent In Vitro Antileishmanial Activity: Initial SAR and Assessment of In Vivo Activity. Journal of Medicinal Chemistry, 2020, 63, 9523-9539.	6.4	8
20	Identification of 6-amino-1H-pyrazolo[3,4-d]pyrimidines with in vivo efficacy against visceral leishmaniasis. RSC Medicinal Chemistry, 2020, 11, 1168-1177.	3.9	2
21	Discovery and Optimization of a Compound Series Active against Trypanosoma cruzi, the Causative Agent of Chagas Disease. Journal of Medicinal Chemistry, 2020, 63, 3066-3089.	6.4	8
22	The Q_i Site of Cytochrome b is a Promiscuous Drug Target in Trypanosoma cruzi and Leishmania donovani. ACS Infectious Diseases, 2020, 6, 515-528.	3.8	23
23	Discovery of an Allosteric Binding Site in Kinetoplastid Methionyl-tRNA Synthetase. ACS Infectious Diseases, 2020, 6, 1044-1057.	3.8	11
24	Identification of inhibitors of an unconventional Trypanosoma brucei kinetochore kinase. PLoS ONE, 2019, 14, e0217828.	2.5	6
25	Substituted Aminoacetamides as Novel Leads for Malaria Treatment. ChemMedChem, 2019, 14, 1329-1335.	3.2	5
26	Optimisation of a key cross-coupling reaction towards the synthesis of a promising antileishmanial compound. Tetrahedron Letters, 2019, 60, 1243-1247.	1.4	2
27	Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7015-7020.	7.1	94
28	Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9318-9323.	7.1	119
29	Characterising covalent warhead reactivity. Bioorganic and Medicinal Chemistry, 2019, 27, 2066-2074.	3.0	71
30	Small Polar Hits against S. aureus: Screening, Initial Hit Optimization, and Metabolomic Studies. ACS Omega, 2019, 4, 19199-19215.	3.5	2
31	Validation of Plasmodium falciparum dUTPase as the target of 5â€²-tritylated deoxyuridine analogues with anti-malarial activity. Malaria Journal, 2019, 18, 392.	2.3	7
32	Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2019, 62, 1180-1202.	6.4	33
33	Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani. ACS Infectious Diseases, 2019, 5, 111-122.	3.8	55
34	Development of Chemical Proteomics for the Folateome and Analysis of the Kinetoplastid Folateome. ACS Infectious Diseases, 2018, 4, 1475-1486.	3.8	1
35	Clinical and veterinary trypanocidal benzoxaboroles target CPSF3. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 9616-9621.	7.1	90
36	A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant N-Myristoyltransferase Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 8374-8389.	6.4	41

#	Article	IF	Citations
37	Antitrypanosomal 8-Hydroxy-Naphthyridines Are Chelators of Divalent Transition Metals. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	12
38	2,4-Diamino-6-methylpyrimidines for the potential treatment of Chagasâ€™ disease. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3025-3030.	2.2	5
39	Challenges and recent progress in drug discovery for tropical diseases. Nature, 2018, 559, 498-506.	27.8	164
40	Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis. Nature, 2018, 560, 192-197.	27.8	112
41	Exhaustive sampling of the fragment space associated to a molecule leading to the generation of conserved fragments. Chemical Biology and Drug Design, 2018, 91, 655-667.	3.2	7
42	Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need. Nature Reviews Microbiology, 2017, 15, 217-231.	28.6	315
43	Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani. ACS Infectious Diseases, 2017, 3, 718-727.	3.8	22
44	Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi. Journal of Medicinal Chemistry, 2017, 60, 7284-7299.	6.4	31
45	Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 9790-9806.	6.4	14
46	Fragment library design, synthesis and expansion: nurturing a synthesis and training platform. Drug Discovery Today, 2017, 22, 43-56.	6.4	35
47	Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetase. ACS Infectious Diseases, 2017, 3, 34-44.	3.8	45
48	Screening a protein kinase inhibitor library against Plasmodium falciparum. Malaria Journal, 2017, 16, 446.	2.3	12
49	Validation of N-myristoyltransferase as Potential Chemotherapeutic Target in Mammal-Dwelling Stages of Trypanosoma cruzi. PLoS Neglected Tropical Diseases, 2016, 10, e0004540.	3.0	25
50	Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy. Journal of Medicinal Chemistry, 2016, 59, 9672-9685.	6.4	66
51	Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials. Journal of Medicinal Chemistry, 2016, 59, 6101-6120.	6.4	13
52	Discovery of Inhibitors of Trypanosoma brucei by Phenotypic Screening of a Focused Protein Kinase Library. ChemMedChem, 2015, 10, 1809-1820.	3.2	15
53	Development of Smallâ€Molecule Trypanosoma brucei Nâ€Myristoyltransferase Inhibitors: Discovery and Optimisation of a Novel Binding Mode. ChemMedChem, 2015, 10, 1821-1836.	3.2	20
54	N-Myristoyltransferase Is a Cell Wall Target in Aspergillus fumigatus. ACS Chemical Biology, 2015, 10, 1425-1434.	3.4	38

#	Article	IF	Citations
55	A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature, 2015, 522, 315-320.	27.8	353
56	Application of RNAi to Genomic Drug Target Validation in Schistosomes. PLoS Neglected Tropical Diseases, 2015, 9, e0003801.	3.0	33
57	Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability. Biochemical Journal, 2015, 465, 479-488.	3.7	16
58	Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei. Journal of Medicinal Chemistry, 2015, 58, 7695-7706.	6.4	28
59	Discovery and optimisation studies of antimalarial phenotypic hits. European Journal of Medicinal Chemistry, 2015, 103, 530-538.	5.5	16
60	Characterization of a Melamino Nitroheterocycle as a Potential Lead for the Treatment of Human African Trypanosomiasis. Antimicrobial Agents and Chemotherapy, 2014, 58, 5747-5757.	3.2	2
61	Erratum for De Rycker et al., Comparison of a High-Throughput High-Content Intracellular Leishmania donovani Assay with an Axenic Amastigote Assay. Antimicrobial Agents and Chemotherapy, 2014, 58, 7622-7622.	3.2	1
62	Lead Optimization of a Pyrazole Sulfonamide Series of Trypanosoma brucei N-Myristoyltransferase Inhibitors: Identification and Evaluation of CNS Penetrant Compounds as Potential Treatments for Stage 2 Human African Trypanosomiasis. Journal of Medicinal Chemistry, 2014, 57, 9855-9869.	6.4	57
63	Probing the substrate specificity ofTrypanosoma bruceiGlcNAc-PI de-N-acetylase with synthetic substrate analogues. Organic and Biomolecular Chemistry, 2014, 12, 1919-1934.	2.8	6
64	Fragment screening reveals salicylic hydroxamic acid as an inhibitor of Trypanosoma brucei GPI GlcNAc-PI de-N-acetylase. Carbohydrate Research, 2014, 387, 54-58.	2.3	11
65	Target-based drug discovery for human African trypanosomiasis: selection of molecular target and chemical matter. Parasitology, 2014, 141, 28-36.	1.5	30
66	Fragment-based hit identification: thinking in 3D. Drug Discovery Today, 2013, 18, 1221-1227.	6.4	132
67	Discovery and Structureâ€“Activity Relationships of Pyrrolone Antimalarials. Journal of Medicinal Chemistry, 2013, 56, 2975-2990.	6.4	62
68	Drug Discovery for Neglected Diseases: Molecular Target-Based and Phenotypic Approaches. Journal of Medicinal Chemistry, 2013, 56, 7719-7726.	6.4	158
69	Discovery of Î²2 Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor. ACS Medicinal Chemistry Letters, 2013, 4, 1005-1010.	2.8	65
70	Investigation of acyclic uridine amide and 5â€²-amido nucleoside analogues as potential inhibitors of the Plasmodium falciparum dUTPase. Bioorganic and Medicinal Chemistry, 2013, 21, 5876-5885.	3.0	5
71	Comparison of a High-Throughput High-Content Intracellular Leishmania donovani Assay with an Axenic Amastigote Assay. Antimicrobial Agents and Chemotherapy, 2013, 57, 2913-2922.	3.2	135
72	Handling Uncertainty in Dynamic Models: The Pentose Phosphate Pathway in Trypanosoma brucei. PLoS Computational Biology, 2013, 9, e1003371.	3.2	40

#	Article	IF	Citations
73	Exploring the Trypanosoma brucei Hsp83 Potential as a Target for Structure Guided Drug Design. PLoS Neglected Tropical Diseases, 2013, 7, e2492.	3.0	34
74	Structureâ€“Activity Relationship Studies of Pyrrolone Antimalarial Agents. ChemMedChem, 2013, 8, 1537-1544.	3.2	32
75	From Onâ€Target to Offâ€Target Activity: Identification and Optimisation of Trypanosoma brucei GSK3 Inhibitors and Their Characterisation as Antiâ€Trypanosoma brucei Drug Discovery Lead Molecules. ChemMedChem, 2013, 8, 1127-1137.	3.2	30
76	Whole Organism High-Content Screening by Label-Free, Image-Based Bayesian Classification for Parasitic Diseases. PLoS Neglected Tropical Diseases, 2012, 6, e1762.	3.0	93
77	Automated design of ligands to polypharmacological profiles. Nature, 2012, 492, 215-220.	27.8	698
78	Synthesis and Evaluation of Î±-Thymidine Analogues as Novel Antimalarials. Journal of Medicinal Chemistry, 2012, 55, 10948-10957.	6.4	36
79	Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 140-152.	6.4	102
80	Quinol derivatives as potential trypanocidal agents. Bioorganic and Medicinal Chemistry, 2012, 20, 1607-1615.	3.0	17
81	Design, Synthesis and Biological Evaluation of Trypanosoma brucei Trypanothione Synthetase Inhibitors. ChemMedChem, 2012, 7, 95-106.	3.2	42
82	Dihydroquinazolines as a Novel Class of Trypanosoma brucei Trypanothione Reductase Inhibitors: Discovery, Synthesis, and Characterization of their Binding Mode by Protein Crystallography. Journal of Medicinal Chemistry, 2011, 54, 6514-6530.	6.4	110
83	Target Validation: Linking Target and Chemical Properties to Desired Product Profile. Current Topics in Medicinal Chemistry, 2011, 11, 1275-1283.	2.1	99
84	Finding New Hits in Neglected Disease Projects: Target or Phenotypic Based Screening?. Current Topics in Medicinal Chemistry, 2011, 11, 1284-1291.	2.1	28
85	Investigation of copper(II) tetrafluoroborate catalysed epoxide opening. Tetrahedron Letters, 2011, 52, 7091-7094.	1.4	12
86	Î²-Branched acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase. Bioorganic and Medicinal Chemistry, 2011, 19, 2378-2391.	3.0	24
87	Synthetic arylquinuclidine derivatives exhibit antifungal activity against Candida albicans, Candida tropicalis and Candida parapsilopsis. Annals of Clinical Microbiology and Antimicrobials, 2011, 10, 3.	3.8	17
88	Modified 5â€²â€Trityl Nucleosides as Inhibitors of Plasmodium falciparum dUTPase. ChemMedChem, 2011, 6, 309-320.	3.2	18
89	Design, Synthesis and Biological Evaluation of Novel Inhibitors of Trypanosoma brucei Pteridine Reductaseâ€…1. ChemMedChem, 2011, 6, 302-308.	3.2	39
90	Design, Synthesis, and Evaluation of 5â€²â€Diphenyl Nucleoside Analogues as Inhibitors of the Plasmodium falciparum dUTPase. ChemMedChem, 2011, 6, 1816-1831.	3.2	30

#	Article	IF	Citations
91	Optimisation of the Antiâ€Trypanosoma brucei Activity of the Opioid Agonist U50488. ChemMedChem, 2011, 6, 1832-1840.	3.2	7
92	Identification of Inhibitors of the Leishmania cdc2â€Related Protein Kinase CRK3. ChemMedChem, 2011, 6, 2214-2224.	3.2	45
93	Site-directed mutagenesis provides insights into the selective binding of trityl derivatives to Plasmodium falciparum dUTPase. European Journal of Medicinal Chemistry, 2011, 46, 3309-3314.	5.5	9
94	Evaluation of three novel azasterols against Toxoplasma gondii. Veterinary Parasitology, 2011, 177, 157-161.	1.8	15
95	Structural basis for the efficient phosphorylation of AZT-MP (3â€²-azido-3â€²-deoxythymidine) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Journal, 2010, 428, 499-509.	3.7	38
96	Aryl Phosphoramidates of 5-Phospho Erythronohydroxamic Acid, A New Class of Potent Trypanocidal Compounds. Journal of Medicinal Chemistry, 2010, 53, 6071-6078.	6.4	52
97	Water-soluble polymerâ€“drug conjugates for combination chemotherapy against visceral leishmaniasis. Bioorganic and Medicinal Chemistry, 2010, 18, 2559-2565.	3.0	22
98	Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase. Bioorganic and Medicinal Chemistry, 2010, 18, 5056-5062.	3.0	26
99	Potential application of thymidylate kinase in nucleoside analogue activation in Plasmodium falciparum. Bioorganic and Medicinal Chemistry, 2010, 18, 7302-7309.	3.0	18
100	Design and preparation of sterol mimetics as potential antiparasitics. Bioorganic and Medicinal Chemistry, 2010, 18, 7291-7301.	3.0	7
101	Acetazolamide-based fungal chitinase inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 8334-8340.	3.0	46
102	Selective delivery of 2-hydroxy APA to Trypanosoma brucei using the melamine motif. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4364-4366.	2.2	14
103	Exploring new inhibitors of Plasmodium falciparum purine nucleoside phosphorylase. European Journal of Medicinal Chemistry, 2010, 45, 5140-5149.	5.5	22
104	N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature, 2010, 464, 728-732.	27.8	272
105	Chemical Validation of Trypanothione Synthetase. Journal of Biological Chemistry, 2009, 284, 36137-36145.	3.4	68
106	Improved Tricyclic Inhibitors of Trypanothione Reductase by Screening and Chemical Synthesis. ChemMedChem, 2009, 4, 1333-1340.	3.2	63
107	Synthesis and Evaluation of 1â€(1â€(Benzo[b]thiophenâ€2â€yl)cyclohexyl)piperidine (BTCP) Analogues as Inhibitors of Trypanothione Reductase. ChemMedChem, 2009, 4, 1341-1353.	3.2	45
108	Investigation of Trypanothione Reductase as a Drug Target in Trypanosoma brucei. ChemMedChem, 2009, 4, 2060-2069.	3.2	54

#	Article	IF	Citations
109	SAR studies on azasterols as potential anti-trypanosomal and anti-leishmanial agents. Bioorganic and Medicinal Chemistry, 2009, 17, 5950-5961.	3.0	20
110	Design, synthesis and evaluation of novel uracil acetamide derivatives as potential inhibitors of Plasmodium falciparum dUTP nucleotidohydrolase. European Journal of Medicinal Chemistry, 2009, 44, 678-688.	5.5	43
111	Targeted delivery of compounds to Trypanosoma brucei using the melamine motif. Bioorganic and Medicinal Chemistry, 2009, 17, 2512-2523.	3.0	29
112	N-(2-hydroxypropyl)methacrylamideâ€“amphotericin B (HPMAâ€“AmB) copolymer conjugates as antileishmanial agents. International Journal of Antimicrobial Agents, 2009, 33, 441-448.	2.5	67
113	One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening. Journal of Medicinal Chemistry, 2009, 52, 4454-4465.	6.4	96
114	Kinetic properties and inhibition of the dimeric dUTPase-dUDPase fromCampylobacter jejuni. Journal of Enzyme Inhibition and Medicinal Chemistry, 2009, 24, 111-116.	5.2	8
115	Novel functionalized melamine-based nitroheterocycles: synthesis and activity against trypanosomatid parasites. Organic and Biomolecular Chemistry, 2009, 7, 1154.	2.8	26
116	Thiolactomycin analogues as potential anti-Toxoplasma gondii agents. Parasitology International, 2009, 58, 411-415.	1.3	23
117	Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases. ChemMedChem, 2008, 3, 435-444.	3.2	409
118	Synthesis and testing of peptides for anti-prion activity. European Journal of Medicinal Chemistry, 2008, 43, 2418-2427.	5.5	4
119	Mechanistic Insights into the Cure of Prion Disease by Novel Antiprion Compounds. Journal of Virology, 2007, 81, 10729-10741.	3.4	16
120	Kinetic Characterization of Squalene Synthase from Trypanosoma cruzi: Selective Inhibition by Quinuclidine Derivatives. Antimicrobial Agents and Chemotherapy, 2007, 51, 2123-2129.	3.2	55
121	Inhibitors of Trypanosoma brucei 6-Phosphogluconate Dehydrogenase. Current Bioactive Compounds, 2007, 3, 161-169.	0.5	6
122	Azasterols impair Giardia lamblia proliferation and induces encystation. Biochemical and Biophysical Research Communications, 2007, 363, 310-316.	2.1	14
123	Quinuclidine Derivatives as Potential Antiparasitics. Antimicrobial Agents and Chemotherapy, 2007, 51, 4049-4061.	3.2	40
124	Synthesis and Biological Evaluation of Phosphate Prodrugs of 4â€Phosphoâ€<scp>D</scp> â€erythronohydroxamic Acid, an Inhibitor of 6â€Phosphogluconate Dehydrogenase. ChemMedChem, 2007, 2, 1169-1180.	3.2	27
125	Alterations on the growth and ultrastructure of Leishmania chagasi induced by squalene synthase inhibitors. Veterinary Parasitology, 2007, 146, 25-34.	1.8	30
126	Crystal structures of a bacterial 6â€phosphogluconate dehydrogenase reveal aspects of specificity, mechanism and mode of inhibition by analogues of highâ€energy reaction intermediates. FEBS Journal, 2007, 274, 275-286.	4.7	25

#	Article	IF	Citations
127	Target assessment for antiparasitic drug discovery. Trends in Parasitology, 2007, 23, 589-595.	3.3	130
128	Targeting of Toxic Compounds to the Trypanosome's Interior. Advances in Parasitology, 2006, 63, 125-183.	3.2	52
129	Acyclic Nucleoside Analogues as Inhibitors ofPlasmodiumfalciparumdUTPase. Journal of Medicinal Chemistry, 2006, 49, 4183-4195.	6.4	57
130	Evaluation of Azasterols as Anti-Parasitics. Journal of Medicinal Chemistry, 2006, 49, 6094-6103.	6.4	62
131	Design, synthesis and evaluation of novel uracil amino acid conjugates for the inhibition of Trypanosoma cruzi dUTPase. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3809-3812.	2.2	18
132	New Azasterols against Trypanosoma brucei : Role of 24-Sterol Methyltransferase in Inhibitor Action. Antimicrobial Agents and Chemotherapy, 2006, 50, 2595-2601.	3.2	37
133	Effects of Inhibitors of Î”24(25)-Sterol Methyl Transferase on the Ultrastructure of Epimastigotes ofTrypanosoma cruzi. Microscopy and Microanalysis, 2005, 11, 506-515.	0.4	25
134	Design, synthesis and evaluation of 2,4-diaminoquinazolines as inhibitors of trypanosomal and leishmanial dihydrofolate reductase. Bioorganic and Medicinal Chemistry, 2005, 13, 2637-2649.	3.0	58
135	Biphenylquinuclidines as inhibitors of squalene synthase and growth of parasitic protozoa. Bioorganic and Medicinal Chemistry, 2005, 13, 3519-3529.	3.0	41
136	Preparation of transition-state analogues of sterol 24-methyl transferase as potential anti-parasitics. Bioorganic and Medicinal Chemistry, 2005, 13, 5435-5453.	3.0	35
137	Analogues of Thiolactomycin as Potential Antimalarial Agents. Journal of Medicinal Chemistry, 2005, 48, 5932-5941.	6.4	95
138	dUTPase as a Platform for Antimalarial Drug Design: Structural Basis for the Selectivity of a Class of Nucleoside Inhibitors. Structure, 2005, 13, 329-338.	3.3	81
139	Interaction of Monobenzamidine-Linked Trypanocides with the Trypanosoma brucei P2 Aminopurine Transporter. Antimicrobial Agents and Chemotherapy, 2005, 49, 5169-5171.	3.2	11
140	Deoxyuridine Triphosphate Nucleotidohydrolase as a Potential Antiparasitic Drug Target. Journal of Medicinal Chemistry, 2005, 48, 5942-5954.	6.4	67
141	Design and Synthesis of a Series of Melamine-based Nitroheterocycles with Activity against Trypanosomatid Parasites. Journal of Medicinal Chemistry, 2005, 48, 5570-5579.	6.4	153
142	6-Phosphogluconate Dehydrogenase: A Target for Drugs in African Trypanosomes. Current Medicinal Chemistry, 2004, 11, 2639-2650.	2.4	29
143	Trypanocidal Activity of Melamine-Based Nitroheterocycles. Antimicrobial Agents and Chemotherapy, 2004, 48, 1733-1738.	3.2	56
144	Novel Azasterols as Potential Agents for Treatment of Leishmaniasis and Trypanosomiasis. Antimicrobial Agents and Chemotherapy, 2004, 48, 2937-2950.	3.2	93

#	Article	IF	Citations
145	Synthesis of Analogues of Congo Red and Evaluation of Their Anti-Prion Activity. Journal of Medicinal Chemistry, 2004, 47, 5515-5534.	6.4	57
146	Analogues of thiolactomycin as potential anti-malarial and anti-trypanosomal agents. Bioorganic and Medicinal Chemistry, 2004, 12, 683-692.	3.0	77
147	Design, synthesis and evaluation of potential inhibitors of HIV gp120â€“CD4 interactions. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2673-2676.	2.2	10
148	Selective Inhibition of Trypanosoma brucei 6-Phosphogluconate Dehydrogenase by High-Energy Intermediate and Transition-State Analogues. Journal of Medicinal Chemistry, 2004, 47, 3427-3437.	6.4	33
149	2,4-Diaminopyrimidines as inhibitors of Leishmanial and Trypanosomal dihydrofolate reductase. Bioorganic and Medicinal Chemistry, 2003, 11, 4693-4711.	3.0	53
150	Synthesis and evaluation of analogues of congo red as potential compounds against transmissible spongiform encephalopathies. European Journal of Medicinal Chemistry, 2003, 38, 567-579.	5.5	49
151	Synthesis and biological evaluation of substrate-Based inhibitors of 6-phosphogluconate dehydrogenase as potential drugs against African Trypanosomiasis. Bioorganic and Medicinal Chemistry, 2003, 11, 3205-3214.	3.0	27
152	Solid-Phase synthesis of diamine and polyamine amino acid derivatives as HIV-1 tat-TAR binding inhibitors. Bioorganic and Medicinal Chemistry, 2003, 11, 87-94.	3.0	13
153	Azasterols as Inhibitors of Sterol 24-Methyltransferase in Leishmania Species and Trypanosoma cruzi. Journal of Medicinal Chemistry, 2003, 46, 4714-4727.	6.4	96
154	Synthesis of (R)-2-methyl-4-deoxy and (R)-2-methyl-4,5-dideoxy analogues of 6-phosphogluconate as potential inhibitors of 6-phosphogluconate dehydrogenaseElectronic supplementary information (ESI) available: experimental procedure and spectroscopic data (1H NMR, 13C NMR, DEPT) for compounds 2, 12, 13, 14, 15 and 21b and the previous synthetic approach tried for the synthesis of (2R)-2-methyl-4,5-dideoxy analogues. See http://www.rsc.org/suppdata/ob/b2/b210606j/. Organic and Biomolecular Chemistry, 2003, 1, 552-559.	2.8	10
155	Antiplasmodial activity of a series of 1,3,5-triazine-substituted polyamines. Journal of Antimicrobial Chemotherapy, 2003, 52, 290-293.	3.0	25
156	In vitro cell-free conversion of bacterial recombinant PrP to PrPres as a model for conversion. Journal of General Virology, 2003, 84, 1013-1020.	2.9	63
157	Synthesis of Potential Anti-HIV GP120 Inhibitors Using a Lysine Template. Journal of Enzyme Inhibition and Medicinal Chemistry, 2002, 17, 175-182.	5.2	0
158	Synthesis and Testing of 5-Benzyl-2,4-diaminopyrimidines as Potential Inhibitors of Leishmanial and Trypanosomal Dihydrofolate Reductase. Journal of Enzyme Inhibition and Medicinal Chemistry, 2002, 17, 293-302.	5.2	16
159	Perspectives for New Drugs Against Trypanosomiasis and Leishmaniasis. Current Topics in Medicinal Chemistry, 2002, 2, 471-482.	2.1	48
160	Inhibitors of dihydrofolate reductase in leishmania and trypanosomes. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2002, 1587, 249-257.	3.8	94
161	Design, synthesis and evaluation of peptide libraries as potential anti-HIV compounds, via inhibition of gp120/cell membrane interactions, using the gp120/cd4/fab17 crystal structure. European Journal of Medicinal Chemistry, 2002, 37, 883-890.	5.5	15
162	Nitrile Reduction in the Presence of Boc-Protected Amino Groups by Catalytic Hydrogenation over Palladium-Activated Raney-Nickel. Journal of Organic Chemistry, 2001, 66, 2480-2483.	3.2	46

#	Article	IF	Citations
163	Synthesis and Biological Evaluation ofs-Triazine Substituted Polyamines as Potential New Anti-Trypanosomal Drugs. Journal of Medicinal Chemistry, 2001, 44, 3440-3452.	6.4	135
164	Novel inhibitors of Trypanosoma cruzi dihydrofolate reductase. European Journal of Medicinal Chemistry, 2001, 36, 395-405.	5.5	69
165	Novel inhibitors of leishmanial dihydrofolate reductase. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 977-980.	2.2	44
166	Rapid and sensitive quantitation of antibiotics in fermentations by electrospray mass spectrometry. Rapid Communications in Mass Spectrometry, 2001, 15, 1229-1238.	1.5	12
167	Selective inhibition of 6-phosphogluconate dehydrogenase from Trypanosoma brucei. Journal of Computer-Aided Molecular Design, 2001, 15, 465-475.	2.9	13
168	Molecular dynamics simulations of wild-type and point mutation human prion protein at normal and elevated temperature. Journal of Molecular Graphics and Modelling, 2001, 20, 145-154.	2.4	55
169	Squalamine analogues as potential anti-trypanosomal and anti-leishmanial compounds. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 1237-1239.	2.2	28
170	A QSAR study investigating the effect of l-alanine ester variation on the anti-HIV activity of some phosphoramidate derivatives of d4T. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 2075-2078.	2.2	18
171	Solid Phase Synthesis of Purines from Pyrimidines. ACS Combinatorial Science, 2000, 2, 249-253.	3.3	39
172	Screening Congo Red and its analogues for their ability to prevent the formation of PrP-res in scrapie-infected cells. Journal of General Virology, 2000, 81, 1155-1164.	2.9	89
173	The structure-based design and synthesis of selective inhibitors of trypanosoma cruzi dihydrofolate reductase. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 1463-1468.	2.2	32
174	Design, Synthesis, and Evaluation of Inhibitors of Trypanosomal and Leishmanial Dihydrofolate Reductase. Journal of Medicinal Chemistry, 1999, 42, 4300-4312.	6.4	79
175	Design and Synthesis of Lipophilic Phosphoramidate d4T-MP Prodrugs Expressing High Potency Against HIV in Cell Culture:â€‰ Structural Determinants for in Vitro Activity and QSAR. Journal of Medicinal Chemistry, 1999, 42, 4122-4128.	6.4	61
176	Dihydrofolate reductase: a potential drug target in trypanosomes and leishmania. Journal of Computer-Aided Molecular Design, 1998, 12, 241-257.	2.9	55
177	Electrospray Mass Spectrometry for Assay of Erythromycin A Extracted From Fermentation Liquor. Biotechnology Letters, 1998, 12, 435-438.	0.5	2
178	An approach to use an unusual adenosine transporter to selectively deliver polyamine analogues to trypanosomes. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 811-816.	2.2	45
179	Design and synthesis of bio-isosteres of thymidine triphosphate. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 1211-1214.	2.2	4
180	The design and synthesis of nucleoside triphosphate isosteres as potential inhibitors of HIV reverse transcriptase. Tetrahedron, 1997, 53, 5537-5562.	1.9	20

#	Article	IF	Citations
181	Lipophilic bioisosteres of nucleoside triphosphates. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 2411-2416.	2.2	9
182	Isosteres of nucleoside triphosphates. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 2405-2410.	2.2	10
183	Imidazolines as amide bond replacements. Tetrahedron, 1995, 51, 6315-6336.	1.9	38
184	Synthesis of Î²-keto and Î±,Î²-unsaturated N-acetylcysteamine thioesters. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 1587-1590.	2.2	44
185	Synthesis of a homochiral Î±,Î±-disubstituted Î±,Î²-diamino-acid. Tetrahedron: Asymmetry, 1994, 5, 1661-1664.	1.8	17
186	Lewis acid-catalysed rearrangements of myo-inositol orthoformate derivatives. Carbohydrate Research, 1992, 234, 117-130.	2.3	37
187	Amide bond replacements : incorporation of a 2,5,5-trisubstituted imidazoline into dipeptides and into a CCK-4 derivative.. Tetrahedron Letters, 1991, 32, 2277-2280.	1.4	19
188	Synthesis of protected myo-inositols. Tetrahedron Letters, 1990, 31, 2633-2634.	1.4	22